A look at the science and clinical results of a novel, super-oxidized antiseptic solution in the treatment of wounds
Table of Contents
Super-Oxidized Dermacyn in Lower-Extremity Wounds
Introduction and early experience .............................................................page 3
David E. Allie, MDCardiovascular Institute of the South Lafayette, LA
The Science Behind Stable, Super-Oxidized Water
Exploring the various applications of super-oxidized solutions......................page 7
Andrés A. Gutiérrez, MD, PhD Oculus Innovative Sciences Petaluma, California
Advanced Wound Care with Stable, Super-Oxidized Water
A look at how combination therapy can optimize wound healing...............page 11
Tom A. Wolvos, MD, FACS Scottsdale Healthcare Wound Management Services Scottsdale, Arizona
Treating Diabetic Foot Ulcers with Super-Oxidized Water
A look at advances in this pH-neutral, non-toxic treatment .........................page 14
Luca Dalla Paola, MD Diabetic Foot Department, Foot & Ankle Clinic Abano Terme Hospital, Abano Terme, Italy
Reducing Bacterial InfectiousComplications from Burn Wounds
A look at the use of Oculus Microcyn60 to treat wounds in Mexico ...........page 17
Ariel Miranda Altamirano, MD Pediatric Burn Unit Hosptial Civil, Guadalajara, Mexico
Super-Oxidized Microcyn Technology in Lower-Extremity Wounds
Introduction and early experience
David E. Allie, MD
hen considering the spectrum of chronic limb wounds in which infectionplays a clinical role, critical limb ischemia (CLI), diabetic foot ulcers (DFUs), below-knee amputations (BKA), methicillin-resistant Staphylococcus aureus (MRSA), and chronic venous insufficiency (CVI) are sure to come to mind. The role of infection in these conditions may range from minor to severe, but it likely plays a significant role in most cases. This supplement will introduce a novel,local, super-oxidized antiseptic solution, Microcyn® Technology (Oculus Innovative Sciences, Petaluma, Calif), and review the science surrounding its unique mechanism of action and the early clinical experiences from centers in Italy, Mexico, and the United States. The clinical and economical impact of acute and chronic infections in lower-extremity wounds is certainly substantial, but this impact isdwarfed when considering the overall clinical and economical global healthcare impact of infection across the entire spectrum of acute to chronic skin wounds (eg, pressure ulcers, burns, trauma, surgical infections, acne) and acute and chronic respiratory infections (eg, sinusitis, bronchitis, pneumonitis, bird flu).
amputation (PA) still carrying an excessively high mortality rate of13–17%.7–9 In the highest risk patients,10 30-day periprocedural mortality after amputation can range from 4–30% and morbidity from 20–37%, because many endstage CLI patients will suffer from infection, sepsis, and progressive renal insufficiency. Successful rehabilitation after
Successful rehabilitation after below-knee amputation is achieved in less than two-thirds of patients.
BKA is achieved in lessthan two-thirds of patients; after above-the-knee amputations, that fraction is less than one-half of patients. Overall, less than 50% of all patients requiring amputation ever achieve full mobility.11–15 Multiple reports have documented the poor overall prognosis for the CLI patient with mortality rates greater than 50% after 3 years and twice the mortality rate after BKA versus limb salvage.10,16Clearly, the clinical impact of CLI and amputations is staggering, and the overall role of infection in limb loss is poorly understood and certainly under appreciated.
The Reality of Infection and Limb Loss
Between 220,000 and 240,000 lower-extremity amputations are performed in the United States and Europe yearly for arterial insufficiency, diabetes, and CLI.1–5 In the United States,...